Patent: 10,150,787
✉ Email this page to a colleague
Summary for Patent: 10,150,787
Title: | TC-PTP inhibitors as APC activators for immunotherapy |
Abstract: | The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases. ##STR00001## |
Inventor(s): | Tremblay; Michel L. (Montreal, CA), Penafuerte; Claudia (Montreal, CA), Feldhammer; Matthew (Montreal, CA), Zogopoulos; George (Montreal, CA), Black; Cameron (Baie d\'Urfe, CA), Kennedy; Brian (Kirkland, CA) |
Assignee: | |
Application Number: | 15/986,313 |
Patent Claims: | see list of patent claims |
Details for Patent 10,150,787
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2034-02-28 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2034-02-28 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2034-02-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |